Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) was held in Frankfurt, Germany, both online and offline. The conference was hosted by the European Hematology Association. As the largest international conference in the European hematology field, it attracts over 10,000 professionals from more than 100 countries each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At the EHA conference site, Oncology Frontier specially invited Professor Niels Van de Donk from Amsterdam University Medical Center (AMC-UvA) to interpret the latest research and future direction of CAR-T in the treatment of relapsed/refractory multiple myeloma (RRMM)
Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian's team from Peking University People's Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the conference, the "Tumor Watch" publication interviewed Dr. Qian Jiang, who elaborated on the current status of CML treatment, future prospects, and the initial intent and primary outcomes of the dosage reduction study.
De-escalation and Escalation Treatment of Early Breast Cancer—Insights from an Interview with Giuseppe Curigliano at SGBCC 2023

De-escalation and Escalation Treatment of Early Breast Cancer—Insights from an Interview with Giuseppe Curigliano at SGBCC 2023

The 18th St. Gallen International Breast Cancer Conference 2023 held in Vienna provided a platform for experts in the field to share their perspectives on the management of early breast cancer. Among the distinguished attendees was Professor Giuseppe Curigliano from the European Institute of Oncology, IRCCS, Milan, Italy. In the interview by Oncology Frontier, he shed light on the concepts of de-escalation and escalation treatment in early breast cancer cases, addressing the potential benefits and challenges in current and upcoming therapeutic strategies.
SGBCC  International Dialogue| Dr. Li Zhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

SGBCC  International Dialogue| Dr. Li Zhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "If you achieve pCR after neoadjuvant, do you need adjuvant therapy?" drew global expert attention. Oncology Frontier had  invited Dr. Li Zhu from Shanghai Jiao Tong University School of Medicine, First People's Hospital, and Dr. Giuseppe Curigliano from the University of Milan School of Medicine to engage in an in-depth discussion on this topic.